[Treatment outcome, survival and their risk factors among new tuberculosis patients co-infected with HIV during the Ebola outbreak in Conakry]. / L'issue du traitement, la survie et ses facteurs de risque chez les nouveaux tuberculeux co-infectés par le VIH pendant l'épidémie d'Ebola à Conakry.

BACKGROUND: Mortality among TB/HIV co-infected patients remains high in Africa. The study aimed to estimate survival and associated factors in a cohort of TB/HIV co-infected patients who started tuberculosis treatment during the Ebola outbreak in Conakry, Guinea. METHODS: A prospective cohort study was conducted from April 2014 to December 2015. TB patients with HIV co-infection were enrolled at the University Hospital of Conakry. Survival and risk factors were analyzed according to Kaplan-Meier's method, log-rank test and Cox's regression. RESULTS: Data from 573 patients were analyzed. From these, 86 (15.0%) died before the end of treatment, 52% occurring within eight weeks of treatment onset. Survival at 4, 12 and 24 weeks after the beginning of the TB treatment was 92%, 86% and 83%, respectively. Independent risk factors associated with death were in the cell CD4 <200 cells/mm3 [adjusted hazard ratio (AHR): 2.25; 95% CI (confidence intervals): 1.16-4.37], opportunistic infections other than TB [AHR: 2.89; 95% CI: 1.39-6.02], and comorbidities [AHR: 4.12; 95% CI: 2.10-8.10]. An increase of one unit in hemoglobin [AHR: 0.81; 95% CI: 0.75-0.91] was protective of death. CONCLUSION: TB/HIV co-infected patients had a higher fatality rate during treatment of tuberculosis. Prevention of opportunistic infections, anemia and proper management of tuberculosis treatment in early comorbidities may improve survival for TB/HIV co-infected patients in restoring immune function.

[Particularities of early neonatal bacterial infection in the hospital environment of the CHU Gabriel Touré in Bamako]. / Particularites de l'infection neonatale bacterienne precoce en milieu hospitalier du CHU Gabriel Toure de Bamako.

INTRODUCTION: Early neonatal bacterial infection (ENBI) is a major concern in neonatology. In Mali, no study had addressed this aspect, hence the initiation of this work to study the epidemiological-clinical, biological and bacteriological profile of ENBI. MATERIALS AND METHODS: This was a descriptive longitudinal study that took place from june 27 to september 3, 2016 involving newborns aged ≤ 72 hours hospitalized for ENBI confirmed by blood culture in the neonatology service of the pediatrics department of the Center Hospitalier et Universitaire (CHU) Gabriel Toure in Bamako. The parameters studied were the socio-demographic and obstetrical characteristics of the mothers, the clinical, biological and bacteriological characteristics of newborns infected early. RESULTS: Of the 324 blood cultures performed, 52 were positive, i.e. an ENBI frequency of 11.04%. The sex ratio was 1.3 with 73.1% low birth weight. On admission, 90.4% of newborns had less than 24 hours of life and 86.5% were births outside the CHU Gabriel Toure. The main clinical signs were hyperthermia or hypothermia and respiratory distress. The main bacteria isolated in blood culture were Staphylococcus aureus (55.8%), Klebsiella pneumoniae (13.5%) and Escherichia coli (07.7%). Sensitivity to first-line biantibiotic therapy (ceftriaxone + gentamicin) was low (63.6%) and that of amikacin was better (100%). Half of the newborns infected early died and 19.2% of exeat without medical agreement was recorded. CONCLUSION: Early neonatal bacterial infection is a major cause of neonatal morbidity and mortality. In our context, amikacin could be a better therapeutic alternative.

INTRODUCTION: L'infection néonatale bactérienne précoce (INBP) est une préoccupation majeure en néonatologie. Au Mali, aucune étude n'avait abordé cet aspect d'où l'initiation du présent travail afin d'étudier le profil épidémio-clinique, biologique et bactériologique de l'INBP. MATÉRIEL ET MÉTHODES: Il s'est agi d'une étude longitudinale descriptive qui s'est déroulée du 27 juin au 03 septembre 2016 ayant concerné les nouveau-nés d'âge ≤ à 72 heures hospitalisés pour INBP confirmée à l'hémoculture dans le service de néonatologie du département de pédiatrie du Centre Hospitalier et Universitaire (CHU) Gabriel Touré de Bamako. Les paramètres étudiés étaient les caractéristiques sociodémographiques et obstétricales des mères, les caractéristiques cliniques, biologiques et bactériologiques des nouveau-nés infectés précocement. RÉSULTATS: Sur les 324 hémocultures réalisées, 52étaient positives soit une fréquence d'INBP de 11,04 %. Le sex-ratio était de 1,3 avec 73,1% de petit poids de naissance. A l'admission, 90,4 % des nouveau-nés avait moins de 24 H de vie et86, 5%étaient des naissances hors du CHU Gabriel Touré. Les principaux signes cliniques étaient l'hyperthermie ou l'hypothermie et la détresse respiratoire. Les principales bactéries isolées à l'hémoculture étaient Staphylococcus aureus (55,8%), Klebsiella pneumoniae (13,5 %) et Escherichia coli(07,7 %). La sensibilité à la biantibiothérapie de première intention (ceftriaxone + gentamicine)était faible (63,6%) et celle de l'amikacine était meilleure (100 %). La moitié des nouveau-nés infectés précocement est décédée et 19,2% d'exéat sans accord médical a été enregistrée. CONCLUSION: L'infection néonatale bactérienne précoce est une cause majeure de morbi-mortalité néonatale. Dans notre contexte, l'amikacine pourrait être une meilleure alternative thérapeutique.